Stock Analysis·← Pickers

NEUP

Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc. (NEUP) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 35.4, with 0/3 trend checks passing.

Price
$3.56
+0.04 (+1.20%)
Day range
$3.49–$3.56
52wk $3.19–$21.40
Volume
841
Avg
Trend score
0/3
Downtrend
RSI (14)
35.4
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

NEUP with MA50 and MA200

20.0015.8411.697.543.3808/0110/2701/2304/2007/16
NEUP2025-08-012026-07-16
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$4.53-21.38% vs price
MA200
$5.37-33.66% vs price
RSI (14)
35.4Neutral zone
MACD Signal
MixedMACD near signal line
Macro Support
$3.65–$3.840.0% below price · 3 touches
Support Quality
3 touches5.3× zone volume
Valuation

NEUP valuation multiples (TTM)

P/E Ratio
P/S Ratio
P/B Ratio
EV/EBITDA
Valuation multiples are provided by Financial Modeling Prep when available.
Analyst Ratings

NEUP analyst consensus

Avg Price Target
High Target
Low Target
Analyst Coverage
Analyst ratings and price targets are provided by Financial Modeling Prep when available.
Chart Summary
Trend summary for NEUP

Neuphoria Therapeutics Inc. (NEUP) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $3.56, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 21.4% and below the 200-day moving average by 33.7%.

Momentum and stretch context

NEUP currently has an RSI reading of 35.4, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.

What traders may watch next

For traders reviewing NEUP next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.

Company profile

About Neuphoria Therapeutics Inc.

Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Spyridon Papapetropoulos
Employees
8
Market cap
$18.9M
Beta
0.75
52-week range
$3.19 – $21.40
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
16 Dec 2021
ISIN
US64136E1029
CUSIP
64136E102
Company profile data from Financial Modeling Prep. NEUP listed on NASDAQ.
Share dilution

NEUP shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Jun 2019Mar 2026
Shares outstanding (latest)
5.4M
Since Jun 2019
-77.6%
Trend
Fewer shares outstanding (buybacks)
Historical shares-outstanding data from Financial Modeling Prep. NEUP28 data points from Jun 2019 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about NEUP

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.